Priothera

Priothera is at the forefront of developing orally applicable sphingosine-1-phosphate (S1P) receptor modulators for hematologic malignancies. S1P receptor modulators significantly reduce the egress of T-cell subsets from lymphoid tissues, thereby dually inhibiting graft-versus-host disease (GvHD) and enhancing the graft-versus-leukemia benefits in patients receiving allogeneic stem cell transplantation.